Skip to main content
SpringerLink
Log in

Positron Emission Tomography (PET) in Germ Cell Tumors (GCT)

  • Chapter
Imaging in Oncological Urology

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Carlsson-Farrelly E, Boquist L, Ljungberg B. Accuracy of clinical staging in non-seminomatous testicular cancer – a single centre experience of retroperitoneal lymph node dissection. Scand J Urol Nephrol. 1995;29(4):501–6.

    PubMed  CAS  Google Scholar 

  2. Fernandez EB, et al. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology. 1994;44(4):548–52.

    Article  PubMed  CAS  Google Scholar 

  3. Rustin GJ, et al. Consensus statement on circulating tumour markers and staging patients with germ cell tumours. Prog Clin Biol Res. 1990;357:277–84.

    PubMed  CAS  Google Scholar 

  4. Kubota R, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33(11):1972–80.

    PubMed  CAS  Google Scholar 

  5. Wilson CB, et al. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med. 1995;22(6):508–13.

    PubMed  CAS  Google Scholar 

  6. Hoekstra OS, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med. 1993;34(10):1706–10.

    PubMed  CAS  Google Scholar 

  7. Wahl RL, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11(11):2101–11.

    PubMed  CAS  Google Scholar 

  8. Engel H, et al. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med. 1996;37(3):441–6.

    PubMed  CAS  Google Scholar 

  9. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36(10):1836–9.

    PubMed  Google Scholar 

  10. Landoni C, et al. Comparison of dual-head coincidence PET versus ring PET in tumor patients. J Nucl Med. 1999;40(10):1617–22.

    PubMed  CAS  Google Scholar 

  11. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2(3):157–64.

    Article  PubMed  CAS  Google Scholar 

  12. Lienhard GE, et al. How cells absorb glucose. Sci Am. 1992;266(1):86–91.

    Article  PubMed  CAS  Google Scholar 

  13. Nabi HA, Zubeldia JM. Clinical applications of (18)F-FDG in oncology. J Nucl Med Technol. 2002;30(1):3–9; quiz 10–1.

    PubMed  Google Scholar 

  14. Kole AC, et al. L-[1-carbon-11]tyrosine imaging of metastatic testicular nonseminoma germ-cell tumors. J Nucl Med. 1998;39(6): 1027–9.

    PubMed  CAS  Google Scholar 

  15. Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics. 1998;18(4):805–23; discussion 823–4.

    PubMed  CAS  Google Scholar 

  16. Cremerius U, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med. 1998;39(5):815–22.

    PubMed  CAS  Google Scholar 

  17. Nuutinen JM, et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer. 1997;33(8):1234–41.

    Article  PubMed  CAS  Google Scholar 

  18. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23(10):1409–15.

    Article  PubMed  CAS  Google Scholar 

  19. Engenhart R, et al. Therapy monitoring of presacral recurrences after high-dose irradiation: value of PET, CT, CEA and pain score. Strahlenther Onkol. 1992;168(4):203–12.

    PubMed  CAS  Google Scholar 

  20. Haberkorn U, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med. 1991;32(8):1485–90.

    PubMed  CAS  Google Scholar 

  21. Cohade C, Wahl RL. PET scanning and measuring the impact of treatment. Cancer J. 2002;8(2):119–34.

    Article  PubMed  Google Scholar 

  22. Hain SF, et al. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med. 2000;27(5):590–4.

    Article  PubMed  CAS  Google Scholar 

  23. Stroobants S, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39(14):2012–20.

    Article  PubMed  CAS  Google Scholar 

  24. Albers P, et al. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology. 1999;53(4):808–11.

    Article  PubMed  CAS  Google Scholar 

  25. Cremerius U, et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicularcancer? – Results of a study in 50 patients. Urology. 1999;54(5):900–4.

    Article  PubMed  CAS  Google Scholar 

  26. Hofer C, et al. Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol. 2001;40(5):481–7.

    Article  PubMed  CAS  Google Scholar 

  27. Muller-Mattheis V, et al. Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors. Urologe A. 1998;37(6):609–20.

    Article  PubMed  CAS  Google Scholar 

  28. Spermon JR, et al. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int. 2002;89(6):549–56.

    Article  PubMed  CAS  Google Scholar 

  29. Tsatalpas P, et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int. 2002;68(3):157–63.

    Article  PubMed  Google Scholar 

  30. De Wit M, Hartmann M, Brenner W, Weiβbach L, Amthauer H, Franzius C, et al. [18F]-FDG-PET in germ cell tumors following chemotherapy: Results of the German multicenter trial. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. 24(18S) (June 20 Suppl) 2006:4521.

    Google Scholar 

  31. Eary JF. Nuclear medicine in cancer diagnosis. Lancet. 1999;354(9181):853–7.

    Article  PubMed  CAS  Google Scholar 

  32. Hustinx R, et al. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol. 1998;9(4):397–401.

    Article  PubMed  CAS  Google Scholar 

  33. Lowe VJ, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 1998;16(3):1075–84.

    PubMed  CAS  Google Scholar 

  34. Moog F, et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16(2):603–9.

    PubMed  CAS  Google Scholar 

  35. Regelink G, et al. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging. 2002;29(8):1024–30.

    Article  PubMed  CAS  Google Scholar 

  36. Spaepen K, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2002;13(9): 1356–63.

    Article  PubMed  CAS  Google Scholar 

  37. Jerusalem G, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol. 2003;14(1):123–30.

    Article  PubMed  CAS  Google Scholar 

  38. Jerusalem G, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94(2):429–33.

    PubMed  CAS  Google Scholar 

  39. Kostakoglu L, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 2002;43(8):1018–27.

    PubMed  Google Scholar 

  40. Schoder H, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(21): 4643–51.

    Article  PubMed  Google Scholar 

  41. Juweid ME, et al. Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005;23(21):4652–61.

    Article  PubMed  Google Scholar 

  42. Stephens AW, et al. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol. 1996;14(5):1637–41.

    PubMed  CAS  Google Scholar 

  43. Donohue JP, et al. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol. 1995;153(1):85–9.

    Article  PubMed  CAS  Google Scholar 

  44. Stephenson AJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. 2005;23(12):2781–8.

    Article  PubMed  Google Scholar 

  45. Gatti JM, Stephenson RA. Staging of testis cancer. Combining serum markers, histologic parameters, and radiographic imaging. Urol Clin North Am. 1998;25(3):397–403.

    Article  PubMed  CAS  Google Scholar 

  46. Hilton S, et al. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol. 1997;169(2):521–5.

    PubMed  CAS  Google Scholar 

  47. Donohue JP, et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol. 1993;149(2):237–43.

    PubMed  CAS  Google Scholar 

  48. Pont J, et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol. 1996;14(2):441–8.

    PubMed  CAS  Google Scholar 

  49. Lassen U, et al. Positron emission tomography with 18F-Fluoro-Deoxyglucose in clinical stage I non-seminomatous germ cell tumors. ASCO Annual Meeting. 2000:1337.

    Google Scholar 

  50. Lassen U, et al. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging. 2003;30(3):396–402.

    PubMed  CAS  Google Scholar 

  51. Huddart RA, O’Doherty MJ, Padhani A, Rustin GJS, Mead GM, Joffe JK, et al. 18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: Preliminary Report of MRC Trial TE22—The NCRI Testis Tumour Clinical Study Group. J Clin Onocol. 2007;3090–5.

    Google Scholar 

  52. Warde P, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002;20(22):4448–52.

    Article  PubMed  Google Scholar 

  53. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, et al. MRC TE19 collaborators and the EORTC 30982 collaborators. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005;366(9482):293–300.

    Article  PubMed  CAS  Google Scholar 

  54. Oliver RT, Mead GM, Fogarty PJ, et al. Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). J Clin Oncol 2008;26 (May 20 suppl; abstr 1).

    Google Scholar 

  55. Donohue JP, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol. 1987;137(6):1176–9.

    PubMed  CAS  Google Scholar 

  56. Toner GC, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol. 1990;8(10):1683–94.

    PubMed  CAS  Google Scholar 

  57. Fizazi K, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy – results from an international study group. J Clin Oncol. 2001;19(10):2647–57.

    PubMed  CAS  Google Scholar 

  58. Loehrer PJ Sr, et al. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. J Urol. 1986;135(6):1183–9.

    PubMed  Google Scholar 

  59. Steyerberg EW, et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol. 1998;16(1):269–74.

    PubMed  CAS  Google Scholar 

  60. Hain SF, et al. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer. 2000;83(7):863–9.

    Article  PubMed  CAS  Google Scholar 

  61. Kollmannsberger C, et al. Prospective comparison of [18F] fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer. 2002;94(9):2353–62.

    Article  PubMed  Google Scholar 

  62. Sanchez D, et al. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int. 2002;89(9):912–6.

    Article  PubMed  CAS  Google Scholar 

  63. Sugawara Y, et al. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology. 1999;211(1):249–56.

    PubMed  CAS  Google Scholar 

  64. De Santis M, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol. 2001;19(17):3740–4.

    PubMed  Google Scholar 

  65. Puc HS, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 1996;14(2):454–60.

    PubMed  CAS  Google Scholar 

  66. Schultz SM, et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol. 1989;7(10):1497–503.

    PubMed  CAS  Google Scholar 

  67. Ganjoo KN, et al. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol. 1999;17(11):3457–60.

    PubMed  CAS  Google Scholar 

  68. De Santis M, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004;22(6):1034–9.

    Article  PubMed  Google Scholar 

  69. Findlay M, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14(3):700–8.

    PubMed  CAS  Google Scholar 

  70. Schelling M, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18(8):1689–95.

    PubMed  CAS  Google Scholar 

  71. Smith IC, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18(8):1676–88.

    PubMed  CAS  Google Scholar 

  72. Bokemeyer C, et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer. 2002;86(4): 506–11.

    Article  PubMed  CAS  Google Scholar 

  73. Beyer J, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol. 1996;14(10):2638–45.

    PubMed  CAS  Google Scholar 

  74. Maszelin P, et al. Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications. Prog Urol. 2000;10(6):1190–9.

    PubMed  CAS  Google Scholar 

  75. Reinhardt MJ, et al. FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy. J Nucl Med. 1997;38(1):99–101.

    PubMed  CAS  Google Scholar 

  76. Wolf G, et al. Diagnosis of a contralateral second testicular carcinoma by F18-FDG PET. Onkologie. 2003;26(2):155–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 3rd Medical Department - Center for Oncology and Hematology Ludwig Boltzmann-Institute for Applied Cancer Research Vienna (LBI-ACR VIEnna), Kaiser Franz Josef - Spital der Stadt Wien and Applied Cancer Research Institution for Translational Research Vienna (ACR-ITR VIEnna)/CEADDP, Kundratstrasse 3, A-1100 Vienna, Austria

    M. De Santis, A. Maj-Hes & M. Bachner

Authors
  1. M. De Santis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Maj-Hes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Bachner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Academic Medical Center, Amsterdam, The Netherlands

    Jean J.M.C.H. de la Rosette  & Hessel Wijkstra  & 

  2. Department of Urology, The George Washington University, Washington, USA

    Michael J. Manyak

  3. Department of Radiology, Massachusetts General Hospital, Boston, DC, USA

    Mukesh G. Harisinghani

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London Limited

About this chapter

Cite this chapter

Santis, M.D., Maj-Hes, A., Bachner, M. (2009). Positron Emission Tomography (PET) in Germ Cell Tumors (GCT). In: de la Rosette, J.J., Manyak, M.J., Harisinghani, M.G., Wijkstra, H. (eds) Imaging in Oncological Urology. Springer, London. https://doi.org/10.1007/978-1-84628-759-6_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-759-6_28

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-514-1

  • Online ISBN: 978-1-84628-759-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation